Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis
CPT: Pharmacometrics & Systems Pharmacology · 2026-05 · 15 (5)
DOI: 10.1002/psp4.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 20.04.2026. Verfasst von Qing Xi Ooi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmetheus, Uppsala, Sweden. Hauptthemen laut MEDLINE: Models, Biological, Liver Cirrhosis, Biliary. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Elafibranor 80 mg/day is approved for second‐line primary biliary cholangitis (PBC) treatment. We present pharmacokinetic (PK) analyses of elafibranor and its metabolite, GFT1007, and pharmacokinetic‐pharmacodynamic (PKPD) analyses describing the relationship between their exposure and responses in alkaline phosphatase (ALP) and total bilirubin (TB). PK data originated from 17 clinical trials. Separate elafibranor and GFT1007 PK models were developed using nonlinear mixed‐effects modeling. Effects of covariates on PK parameters were explored. PKPD data originated from one phase II and one phase III trial; separate ALP and TB models were developed using a sequential approach. The sum of the areas under the plasma‐concentration time curve during a dosing interval at steady state of elafibranor and GFT1007 (AUC τ,ss sum ) from the PK models was used as a driver for drug effects. A joint ALP‐TB model, considering correlations in the inter‐individual variability on selected parameters, was developed and used to perform simulations. Elafibranor and GFT1007 are described by structurally similar two‐compartmental models. Elafibranor has a longer elimination half‐life versus GFT1007 (59.7 versus 10.7 h); predicted time to steady state was 12.4 versus 2.22 days. Covariate effects on the PK of elafibranor and GFT1007 had a limited effect on the PD response of patients receiving the 80 mg/day regimen. Based on PKPD simulations, elafibranor 80 mg/day showed a clear effect and improvement in ALP and TB versus placebo. Saturation in ALP responses was observed for > 30 μmol·h/L, reached by around 60% of patients. These analyses support that elafibranor 80 mg/day is an efficacious PBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmetheus, Uppsala, Sweden.
- Ipsen, Paris, France.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
ORCID-Profile: Qing Xi Ooi, Karl Brendel, Jurij Aguiar Zdovc
Zitieren
APA
Ooi, Q. X., Brendel, K., van Beek, S., Zdovc, J. A., Bardol, M., & Dehez, M. (2026). Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. CPT: Pharmacometrics & Systems Pharmacology, 15(5). https://doi.org/10.1002/psp4.70247
Vancouver
Ooi QX, Brendel K, van Beek S, Zdovc JA, Bardol M, Dehez M. Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(5). doi:10.1002/psp4.70247
BibTeX
@article{Ooi2026,
author = {Ooi, Qing Xi and Brendel, Karl and van Beek, Stijn and Zdovc, Jurij Aguiar and Bardol, Maddlie and Dehez, Marion},
title = {Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/psp4.70247}
}
EUVIMED